New drug TL-003 enters first human tests for ulcerative colitis

NCT ID NCT07526519

Recruiting now Knowledge-focused Sponsor: TrueLab Biopharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug, TL-003, for the first time in humans. The main goal is to check its safety and how the body processes it in 48 healthy adults, with a small group of people who have ulcerative colitis also being studied. Researchers will monitor for side effects and measure drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

TL-003

What this could lead to

If successful, this could pave the way for larger studies testing TL-003 as a potential treatment for ulcerative colitis.

What could go wrong

This is a very early Phase 1 trial with only 48 participants, focused on safety, not effectiveness. The drug may not work or could have side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Linear Early Phase Ltd
RECRUITING

Perth, Western Australia, 6009, Australia